{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/189953932"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "eir intended use and (2) zwitterionic forms, where possible, of the parent compound. [0092] The dosage of the TGF-?? antagonist of the present invention will depend on the disease state or condition being treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "google.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/132732300"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/189953932" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/351009083"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/189953932" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/339442724"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/189953932"] } } }
